These upcoming presentations underscore the breadth and versatility of our ACT-UP1 platform,” said Xuehai Liang, Ph.D., Chief Executive Officer of Arnatar Therapeutics. “By demonstrating the ability ...

The Korea National Institute of Health, under the Korea Disease Control and Prevention Agency, announced on the 17th that it ...

An mRNA cancer vaccine carries its own immune booster and lights up when it starts working, showing treatment success in mice ...

The Wyss team designed a CRISPR RNA therapy able to broadly fight influenza A virus infection and a preclinical system to ...

A defined, xeno-free culture medium from Takara Bio Europe is opening new possibilities for large-scale production of ...

The influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally.

In this free webinar, learn how innovative long RNA manufacturing approaches can drive the development of next-generation RNA medicines. Attendees will ...

"The longevity gene (LAV-BPIFB4) is the first candidate gene capable of rejuvenating a heart damaged by progeria," added ...

In vivo studies demonstrate robust and durable gene silencing across rodents and non-human primates Megalin-targeting ligand-siRNA conjugates ...

引言基因是生命的蓝图，它通过转录(transcription)为信使RNA (messenger RNA, ...